ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,468Medicare Part D Prescriptions Filled, Including Refills

Rank: 123 out of 1006

$554K Total Retail Price of All Prescriptions

Rank: 182 out of 1006

528 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
34% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 528 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

7% of this provider’s 528 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

2% of this provider’s 8,864 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $71 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
LEVOTHYROXINE SODIUM 500 475 1 2
SIMVASTATIN 408 395 2 1
AMLODIPINE BESYLATE 391 387 3 4
HYDROCHLOROTHIAZIDE 325 320 4 11
WARFARIN SODIUM 286 283 5 8
ATORVASTATIN CALCIUM 274 264 6 5
METOPROLOL TARTRATE 271 261 7 7
FUROSEMIDE 260 246 8 6
LISINOPRIL 248 238 9 3
CITALOPRAM HBR 175 175 10 24
LOVASTATIN 157 157 11 44
OMEPRAZOLE 154 152 12 9
QUINAPRIL HCL 146 138 13 86
SERTRALINE HCL 139 121 14 19
METFORMIN HCL 138 134 15 10
ZOLPIDEM TARTRATE 129 113 16 14
SYNTHROID 117 117 17 42
METOPROLOL SUCCINATE 116 112 18 12
PANTOPRAZOLE SODIUM 115 102 19 32
GABAPENTIN 115 86 19 20
TRAZODONE HCL 104 93 21 21
PRAVASTATIN SODIUM 103 83 22 15
HYDROCODONE-ACETAMINOPHEN 96 96 S3 23 25
GLYBURIDE 90 84 R 24 65
PAROXETINE HCL 87 83 25 62
CRESTOR 83 83 26 18
DIOVAN 83 83 26 16
ATENOLOL 79 75 28 13
BENAZEPRIL HCL 74 74 29 112
ACETAMINOPHEN-CODEINE 73 73 S3 30 139
LIPITOR 71 71 31 47
ESCITALOPRAM OXALATE 71 56 31 27
NEXIUM 69 69 33 28
MIRTAZAPINE 68 55 34 26
BENICAR 68 62 34 78
LOSARTAN POTASSIUM 67 66 36 22
JANUVIA 65 57 37 49
ENALAPRIL MALEATE 64 64 38 83
AMLODIPINE BESYLATE-BENAZEPRIL 60 56 39 77
OXYCODONE-ACETAMINOPHEN 58 28 S2 40 57
AZITHROMYCIN 57 57 41 39
CYMBALTA 55 55 42 41
JANTOVEN 50 47 43 171
TAMSULOSIN HCL 50 47 43 23
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 31, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.